Sun Pharma Advanced Research Company Profile
Key Indicators
- Authorised Capital ₹ 42.50 Cr
as on 15-11-2024
- Paid Up Capital ₹ 32.45 Cr
as on 15-11-2024
- Company Age 18 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 175.00 Cr
as on 15-11-2024
- Revenue 73.26%
(FY 2023)
- Profit -9.43%
(FY 2023)
- Ebitda -14.62%
(FY 2023)
- Net Worth 1542.20%
(FY 2023)
- Total Assets 196.39%
(FY 2023)
About Sun Pharma Advanced Research Company
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 532872 and on the National Stock Exchange(NSE) under SPARC.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 42.50 Cr and a paid-up capital of Rs 32.45 Cr.
The company currently has active open charges totaling ₹175.00 Cr.
The Key Managerial Personnel (KMP) at Sun Pharma Advanced Research Company Limited India are Kajal Damania as Company Secretary, Anup Rathi as Cfo, and Anil Kumar as Ceo. Sudhir Valia, Dilip Shanghvi, Bhavna Doshi, and Four other members serve as directors at the Company.
Industry
Company Details
- Location
Vadodara, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sun Pharma Advanced Research Company?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kajal Damania  | Company Secretary | 22-Sep-2023 | Current |
| Anup Rathi | CFO | 20-Jun-2024 | Current |
| Anil Kumar | CEO | 25-May-2021 | Current |
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Robert Spiegel  | Director | 01-Jun-2020 | Current |
| Bhavna Doshi | Director | 31-Oct-2014 | Current |
| Sudhir Valia | Director | 31-Jul-2014 | Current |
| Dilip Shanghvi | Director | 01-Mar-2006 | Current |
| Rajamannar Thennati | Director | 04-Jun-2007 | Current |
| Vidhi Shanghvi | Director | 03-Aug-2024 | Current |
Financial Performance and Corporate Structure Insights of Sun Pharma Advanced Research Company.
Sun Pharma Advanced Research Company Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 73.26% increase. The company also saw a slight decrease in profitability, with a 9.43% decrease in profit. The company's net worth Soared by an impressive increase of 1542.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sun Pharma Advanced Research Company?
In 2023, Sun Pharma Advanced Research Company had a promoter holding of 65.67% and a public holding of 34.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sun Pharmaceutical Industries LimitedActive 31 years 9 monthsSudhir Valia and Dilip Shanghvi are mutual person
Shantilal Shanghvi FoundationActive 20 years 6 monthsSudhir Valia and Dilip Shanghvi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 17 Mar 2022 | ₹25.00 Cr | Open |
Others Creation Date: 18 Feb 2021 | ₹150.00 Cr | Open |
How Many Employees Work at Sun Pharma Advanced Research Company?
Sun Pharma Advanced Research Company has a workforce of 381 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sun Pharma Advanced Research Company, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sun Pharma Advanced Research Company's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
